These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12036895)

  • 21. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
    Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
    Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism.
    Wu CJ; Chillemi A; Alyea EP; Orsini E; Neuberg D; Soiffer RJ; Ritz J
    Blood; 2000 Jan; 95(1):352-9. PubMed ID: 10607724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone marrow T cells are superior to splenic T cells to induce chimeric conversion after non-myeloablative bone marrow transplantation.
    Park HS; Cho SG; Park MJ; Min SY; Chang HS; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Kim CC; Kim HY
    Korean J Intern Med; 2009 Sep; 24(3):252-62. PubMed ID: 19721863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
    Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
    Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation.
    Meyer RG; Wagner EM; Konur A; Bender K; Schmitt T; Hemmerling J; Wehler D; Hartwig UF; Roosnek E; Huber C; Kolbe K; Herr W
    Bone Marrow Transplant; 2010 Apr; 45(4):668-74. PubMed ID: 19684624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism.
    Mapara MY; Kim YM; Marx J; Sykes M
    Transplantation; 2003 Jul; 76(2):297-305. PubMed ID: 12883182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Leda M; Ladon D; Pieczonka A; Boruczkowski D; Jólkowska J; Witt M; Wachowiak J
    Leuk Res; 2001 Apr; 25(4):353-7. PubMed ID: 11248334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants.
    Billiau AD; Fevery S; Rutgeerts O; Landuyt W; Waer M
    Blood; 2002 Sep; 100(5):1894-902. PubMed ID: 12176914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: immunoregulatory aspects and role of donor T and ASGM1-positive cells.
    Sefrioui H; Billiau AD; Waer M
    Transplantation; 2000 Jul; 70(2):348-53. PubMed ID: 10933162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT.
    Johnson BD; Konkol MC; Truitt RL
    Biol Blood Marrow Transplant; 2002; 8(10):525-35. PubMed ID: 12434947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant.
    Beitinjaneh AM; Saliba R; Bashir Q; Shah N; Parmar S; Hosing C; Popat U; Anderlini P; Dinh Y; Qureshi S; Rondon G; Champlin RE; Giralt SA; Qazilbash MH
    Leuk Lymphoma; 2012 Aug; 53(8):1525-9. PubMed ID: 22242817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.
    Huff CA; Fuchs EJ; Noga SJ; O'Donnell PV; Ambinder RF; Diehl L; Borrello I; Vogelsang GB; Miller CB; Flinn IA; Brodsky RA; Marcellus D; Jones RJ
    Biol Blood Marrow Transplant; 2003 May; 9(5):312-9. PubMed ID: 12766881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation.
    Keil F; Kalhs P; Chen X; Haas OA; Fritsch G; Chott A; Lechner K; Moser K; Ackermann J; Rabitsch W; Worel N; Mannhalter C; Greinix HT
    Ann Hematol; 1999 Aug; 78(8):376-9. PubMed ID: 10460352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.
    Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR
    Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adult thymus transplantation with allogeneic intra-bone marrow-bone marrow transplantation from same donor induces high thymopoiesis, mild graft-versus-host reaction and strong graft-versus-tumour effects.
    Miyake T; Hosaka N; Cui W; Nishida T; Takaki T; Inaba M; Kamiyama Y; Ikehara S
    Immunology; 2009 Apr; 126(4):552-64. PubMed ID: 18778285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
    Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of graft-versus-host disease by intrabone marrow injection of donor T cells: involvement of bone marrow stromal cells.
    Miyake T; Inaba M; Fukui J; Ueda Y; Hosaka N; Kamiyama Y; Ikehara S
    Clin Exp Immunol; 2008 Apr; 152(1):153-62. PubMed ID: 18307515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.